Fig. 5 | Nature Communications

Fig. 5

From: Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration

Fig. 5

Spreading of IFNγ signaling in tumor xenografts treated in vivo with galectin antagonists. a Scheme showing the protocol for analyzing IFNγ signal diffusion along the tumor. s.c. stands for subcutaneous injection and I.T. for intratumoral injection. b CXCL9 fold induction along the tumor sections. Mice treated with IFNγ alone (50 ng per tumor), or together with galectin antagonists LacNAc (0.1 μmol per tumor) or antibodies (100 ng per tumor). Mean ± SEM of eight independent tumors for each treatment. For CXCL9 induction in individual tumors see Supplementary Fig. 6a. ***P < 0.0001; Wilcoxon matched-pairs signed rank test with Dunn’s Multiple Comparison Correction Test. The red dotted line marks the threshold of 50 CXCL9 mRNA copies per section of the tumor. Each section represents 0.66 mm thick, contains 30 tumor slices, and about 1–4 millions cells. The drawing below shows the diffusion of CXCL9 gradient along the tumor taking into account the threshold. c Quantification of CXCL9 staining area in immunohistochemistry images of several sections of tumors treated with IFNγ and either a control isotype antibody or an anti-galectin3 ratIgG antibody. Representative images are shown in Supplementary Fig. 7